Sports injuries—affecting bones, muscles, tendons, ligaments, and cartilage—can occur during athletic performance, training, or everyday physical activity. Whether your injury is acute (sudden) or chronic (developing over time), we understand the urgency of returning to peak performance as safely and efficiently as possible.
Depending on the nature and severity of the condition, advanced regenerative therapies such as stem cell–based treatments may support the body’s natural healing processes, potentially reducing recovery time and helping some patients avoid more invasive surgical interventions.
Human umbilical cord tissue–derived mesenchymal stem cells (hUCT-MSCs), including NovaCell Institute’s proprietary Elite Cells, represent a revolutionary advancement in the field of regenerative medicine.
These remarkable cells are renowned for their unique capabilities, which include the modulation of inflammation, the promotion of cellular repair, and the stimulation of tissue regeneration. By harnessing the power of these cells, we can significantly enhance the body’s natural healing processes, making them integral to effective treatment strategies.
The potential applications of hUCT-MSCs extend across a wide spectrum of sports-related injuries, providing promising therapeutic options for conditions such as Achilles tendonitis, which can be notoriously painful and debilitating.
Additionally, these cells are instrumental in the recovery from ligament tears, including the anterior cruciate ligament (ACL) and medial collateral ligament (MCL) injuries, which often plague athletes.
Further, they can aid in the healing of rotator cuff injuries, relieve muscle strains, and assist in the recovery from ailments such as tennis elbow and runner’s knee.
By employing this advanced cellular therapy, athletes can experience a remarkable acceleration in their recovery timelines, enabling them to return to their peak performance levels more swiftly and effectively.
As a result, hUCT-MSCs not only help in healing physical injuries but also allow athletes to regain their competitive edge, ensuring they can perform at their best in their respective sports.
A peer-reviewed study published in 2020 by S. Trebinjac and M. Gharairi, titled “Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries: Clinical Evidence,” highlights the promising role of MSC therapy in sports medicine. The authors concluded that:
“The clinical application of mesenchymal stem cells (MSCs) for the treatment of tendon and ligament injuries may represent a valuable alternative option for athletes. Published clinical studies have demonstrated improvements in both clinical outcomes and the structural integrity of damaged tissues.”
This growing body of evidence supports the use of advanced regenerative therapies, such as NovaCell Institute’s Elite Cells, to help enhance recovery, reduce downtime, and promote stronger tissue healing following sports-related injuries.
Prof. Dr. Ernst von Schwarz is a world-renowned researcher and clinical and academic cardiologist, who has published more than 150 scientific articles in international peer-reviewed journals, several books’ chapters, and books. He is also a sought-after speaker at international scientific conferences worldwide, an expert on stem cell therapy and research, and a public figure in medical media.
I’m back on the field after my knee sidelined me for over a year. My general quality of life has 100% gotten better. Just start [the process] now.
Avoid invasive procedures—no need to collect stem cells from the hip or fat under anesthesia.
A growing body of research suggests that umbilical cord tissue–derived (hUCT) mesenchymal stem cells may exhibit greater biological activity than those from other sources.
No need for mobilization drugs such as granulocyte colony–stimulating factor (G-CSF), which are typically used to stimulate the bone marrow and release stem cells into the bloodstream.
Human umbilical cord tissue–derived mesenchymal stem cells exhibit low immunogenicity, meaning they are less likely to trigger an immune response, and HLA matching is generally unnecessary.
Stem cells can be carefully screened and selected for their superior anti-inflammatory properties, immune-modulating capacity, and regenerative potential.
Allogeneic stem cells can be administered over multiple days in consistent, high-dose treatments to support optimal therapeutic effect.
Umbilical cord tissue is a rich and abundant source of mesenchymal stem cells.
We use NovaCell Institute's Elite Cells, chosen for their quality and effectiveness to support faster healing and better outcomes.
One of our physicians will design your personalized stem cell treatment protocol after reviewing your medical information and confirming your eligibility. Your recommended plan may vary based on your specific condition.
Typical Treatment Schedule (Monday – Thursday | 4 Days):
All-Inclusive Experience in Barranquilla, Colombia:
Your treatment package includes a stay at a premium hotel such as the Hilton Garden Inn Barranquilla, with daily breakfast, high-speed WiFi, and private transportation to and from the airport. You’ll also receive VIP airport assistance with expedited entry for a smooth, stress-free arrival.
Despite extensive scientific research, no stem cell product from any source, including the patient’s own, is approved by the US FDA to treat sports injury.
Check out some of the science here.
However, human umbilical cord tissue-derived mesenchymal stem cells that were isolated and grown in our laboratory to create master cell banks have been used in the United States under US FDA regulation.
The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign, and therefore they are not rejected.
Human umbilical cord tissue stem cells have been administered tens of thousands of times at the NovaCell Institute, and there has never been a single instance of rejection (graft vs. host disease).
As a matter of fact, allogeneic (not the patient’s own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat, and therefore, they are considered to be more “potent”.
The adult stem cells used to treat sports injuries at the NovaCell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Barranquilla, Colombia’s state-of-the-art laboratory.
The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births.
Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.
All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.
Only a small percentage of donated umbilical cords pass our rigorous screening process.
Proper follow-up is an essential part of stem cell therapy. Our primary goal is to ensure that your child is progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 6 months, 9 months, and 1 year to monitor your child’s progress.
You can APPLY TODAY to find out if you are eligible for treatment, and a patient coordinator will reach out to will arrange for a free screening and consultation.
NovaCell Regenerative Medicine by Belleza
Cra 59B 81-143
Barranquilla, Colombia
Outside or Inside US Call:
Phone: +1 (754) 333-6754
Copyright 2026, NovaCell Institute in Barranquilla, Colombia. All rights reserved.
